Research programme: beta cell protection and regeneration therapeutics - DeveloGen
Alternative Names: KuStu 144; Pax4 functional agonistLatest Information Update: 13 Sep 2024
Price :
$50 *
At a glance
- Originator DeveloGen
- Class Azepines
- Mechanism of Action Glycogen synthase kinase 3 beta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 06 Sep 2010 Discontinued - Preclinical for Type-1 diabetes mellitus in Germany (unspecified route)
- 06 Sep 2010 Discontinued - Preclinical for Type-2 diabetes mellitus in Germany (unspecified route)
- 02 Sep 2010 DeveloGen has been acquired by Evotec AG